PPARA and metabolic dysfunction-associated steatotic liver disease: The studies on various experimental models described BBR effects on multiple pathways involved in the progression to NAFLD, and the major ones comprise activation of the SIRT3 pathway, upregulation of SIRT1, activation of AMPK pathway, suppression of NLRP3 pathway, and act as PPAR-Υ agonist (Figure 4, Supplementary Table S1).